Page last updated: 2024-10-15

heliomycin

Description

heliomycin: Russian drug; antibiotic with antiviral properties isolated from Actinomyces flavochromogenes var. heliomycini; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135430323
CHEMBL ID1320139
CHEBI ID29671
SCHEMBL ID2134180
MeSH IDM0051383

Synonyms (50)

Synonym
itamycin
antibiotic a 3733a
croceomycin
a 3733a
geliomycin
brn 2187224
heliomycin [inn]
geliomitsin
heliomycin
2h-benzo(cd)pyrene-2,6(1h)-dione, 3,5,7,10-tetrahydroxy-1,1,9-trimethyl-
resistomycin
20004-62-0
NCGC00160672-01
3,5,7,10-tetrahydroxy-1,1,9-trimethyl-2h-benzo[cd]pyrene-2,6(1h)-dione
NCGC00160275-01
AKOS000715231
NCGC00160275-02
unii-7n3a092a5x
7n3a092a5x ,
4-08-00-03704 (beilstein handbook reference)
3,5,7,10-tetrahydroxy-1,1,9-trimethyl-2h-benzo(c,d)pyrene-2,6(1h)-dione
dtxsid4046101 ,
dtxcid2026101
tox21_111753
cas-20004-62-0
SCHEMBL2134180
CHEMBL1320139
chebi:29671 ,
11029-70-2
x-340
heliomycin [who-dd]
3,5,7,10-tetrahydroxy-1,1,9-trimethyl-2h-benzo(cf)pyrene-2,6(1h)-dione
antibiotic a-3733a
resistomycin [mi]
BRD-K64517075-001-01-9
tox21_111753_1
NCGC00160275-03
heliomycin (salt/mix)
1,2-dihydro-1,1,9-trimethyl-3,5,7,10-tetrahydroxy-6h-benzo[c,d]pyrene-2,6-dione
ABLACSIRCKEUOB-UHFFFAOYSA-N
3,5,7,10-tetrahydroxy-1,1,9-trimethyl-2h-benzo[cd]pyrene-2,6(1h)-dione #
2h-benzo[cf]pyrene-2,6(1h)-dione,3,5,7,10-tetrahydroxy-1,1,9-trimethyl-
SR-01000318568-1
sr-01000318568
J-012937
np285
2,4,10,14-tetrahydroxy-7,7,12-trimethylpentacyclo[13.3.1.05,18.08,17.011,16]nonadeca-1(18),2,4,8,10,12,14,16-octaene-6,19-dione
Q27110219
heliomycin; geliomycin; itamycin
6,10,14,19-tetrahydroxy-4,9,9-trimethylpentacyclo[13.3.1.05,18.08,17.011,16]nonadeca-1(19),3,5,7,10,13,15,17-octaene-2,12-dione

Bioavailability

ExcerptReference
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency1.77830.125919.1169125.8920AID2549
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.76130.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency3.71780.173734.304761.8120AID1346859; AID1346924
Fumarate hydrataseHomo sapiens (human)Potency7.07950.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
GALC proteinHomo sapiens (human)Potency0.316228.183828.183828.1838AID1159614
SMAD family member 3Homo sapiens (human)Potency3.71780.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency4.54960.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency10.93990.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency8.91250.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency1.43970.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.76620.001022.650876.6163AID1224838; AID1224839; AID1224893
EWS/FLI fusion proteinHomo sapiens (human)Potency31.97090.001310.157742.8575AID1259252; AID1259253; AID1259255
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.23910.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency2.25280.003041.611522,387.1992AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.67430.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.88910.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency9.62050.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency1.45750.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.02720.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743079; AID743080; AID743091
polyproteinZika virusPotency7.07950.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency3.20930.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency6.51120.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency3.69770.023723.228263.5986AID743222; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency13.33320.000723.06741,258.9301AID743085
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.57500.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency2.93380.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency9.56480.039147.5451146.8240AID1224845
Bloom syndrome protein isoform 1Homo sapiens (human)Potency10.60240.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency7.07950.010039.53711,122.0200AID1479
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency3.98110.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.60720.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency3.16230.000618.41981,122.0200AID1688
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency8.06140.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.51400.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency4.03530.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency15.84890.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.57970.005612.367736.1254AID624044
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency3.66110.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency1.48320.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency3.66110.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency1.33330.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency1.33330.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (83)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347600Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1657478Antiviral activity against TBEV Absettarov infected in porcine PEK cells assessed as inhibition of viral reproduction by measuring plaque reduction preincubated for 1 hr followed by overlaying with 1.26% methylcellulose and measured after 6 days by gentia2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Simplistic perylene-related compounds as inhibitors of tick-borne encephalitis virus reproduction.
AID1113004Antifungal activity against Fusarium oxysporum f. sp. melongenae assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347628Induction of reactive oxygen species generation in human T24 cells at 1 uM after 30 mins by H2DCFDA dye-based flow cytometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1225306Antimicrobial activity against Escherichia coli ATCC 25922 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1347616Binding affinity to calf thymus double stranded DNA by Benesi-Hildebrand plot analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347618Inhibition of human DNA topoisomerase 1 assessed as decrease in relaxation of pBR322 at 20 uM after 30 to 40 mins by agarose gel electrophoresis2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1225299Antimicrobial activity against Firmicutes K9402015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1113001Antifungal activity against Magnaporthe grisea in fourth-leaf stage of rice plant assessed as curative efficacy at 100 ug/ml after 11 days relative to control2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1225298Antimicrobial activity against Acinetobacter E9062015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1113009Antifungal activity against Valsa mali assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347629Binding affinity to calf thymus DNA2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1882257Antibacterial activity against Escherichia coli LptD4213 assessed as growth inhibition incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 01-28, Volume: 85, Issue:1
Chlororesistoflavins A and B, Chlorinated Benzopyrene Antibiotics Produced by the Marine-Derived Actinomycete
AID1113005Antifungal activity against Fusarium oxysporum f. sp. cucumerinum assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347627Upregulation of total p53 levels in human T24 cells at 0.5 to 1 uM after 18 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347607Antiproliferative activity against HMEC1 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1225297Retention time of the compound by HPLC method2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1113007Antifungal activity against Dothiorella gregaria assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347623Induction of apoptosis n human T24 cells assessed as upregulation of Bak levels at 0.5 to 1 uM after 18 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1225303Antimicrobial activity against Xanthomonas axonopodis ATCC 8718 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1225307Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1882256Antibacterial activity against methicillin-resistant Staphylococcus aureus TCH1516 assessed as growth inhibition incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 01-28, Volume: 85, Issue:1
Chlororesistoflavins A and B, Chlorinated Benzopyrene Antibiotics Produced by the Marine-Derived Actinomycete
AID1347615Binding affinity to calf thymus double stranded DNA at 10 uM by fluorescence spectrophotometer2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347599Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347601Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347621Induction of apoptosis n human T24 cells at 1 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1113010Antifungal activity against Magnaporthe grisea assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1225301Antimicrobial activity against Brucella neotomae ATCC 23459 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1767167Cytotoxicity against human HMEC-1 cells assessed as growth inhibition after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.
AID1347624Induction of apoptosis n human T24 cells assessed as downregulation of Bcl-2 levels at 0.5 to 1 uM after 18 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1657480Cytotoxicity against porcine PEK cells assessed as reduction in cell viability after 7 days by microscopic method2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Simplistic perylene-related compounds as inhibitors of tick-borne encephalitis virus reproduction.
AID1767165Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.
AID1113008Antifungal activity against Fusarium graminearum assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1767166Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.
AID1657479Cytotoxicity against porcine PEK cells assessed as reduction in cell viability after 24 hrs by microscopic method2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Simplistic perylene-related compounds as inhibitors of tick-borne encephalitis virus reproduction.
AID1225300Antimicrobial activity against Burkholderia vietnamiensis ATCC BAA-248 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1225304Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1347626Induction of apoptosis n human T24 cells assessed as PARP cleavage at 0.5 to 1 uM after 18 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1113003Antifungal activity against Magnaporthe grisea assessed as inhibition of spore germination after 12 hr by light microscopic analysis2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347603Antiproliferative activity against mouse L1210 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1113002Antifungal activity against Magnaporthe grisea in fourth-leaf stage of rice plant assessed as preventive efficacy at 100 ug/ml after 11 days relative to control2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1347617Growth inhibition of human T24 cells after 72 hrs by cell impedance method2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1225302Antimicrobial activity against Yersinia pestis A1122 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1347602Antiproliferative activity against human K562/4 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1767164Antiproliferative activity against mouse L1210 cells assessed as growth inhibition after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.
AID1113006Antifungal activity against Rhizoctonia solani assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Feb-20, Volume: 61, Issue:7
Antifungal activities of metabolites produced by a termite-associated Streptomyces canus BYB02.
AID1225305Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of microbial growth at 50 ug/ml2015Journal of natural products, Mar-27, Volume: 78, Issue:3
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture.
AID1347605Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
AID1347604Antiproliferative activity against human CEM cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (42.19)18.7374
1990's3 (4.69)18.2507
2000's9 (14.06)29.6817
2010's13 (20.31)24.3611
2020's12 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]